Cellomatics BioSciences

Executive Summary

Cellomatics BioSciences is a UK-based Contract Research Organisation (CRO) specializing in bespoke preclinical in vitro bioassay development for biotechnology and pharmaceutical clients. Founded in 2017 and headquartered in Nottingham, the company focuses on critical therapeutic areas such as Oncology, Immuno-oncology, Immunology, Inflammation, and Respiratory diseases. By offering complex cell-based models, Cellomatics supports early-stage drug discovery programs, enabling clients to de-risk their candidates before advancing to preclinical stages. As a private, pre-clinical company, Cellomatics operates in a niche segment of the drug development value chain, where demand for specialized, reliable bioassay services is growing due to increasing R&D outsourcing by large pharma and biotechs. Despite its small scale, Cellomatics has positioned itself as a competent partner in a competitive CRO landscape. The company's strength lies in its bespoke approach, allowing it to adapt to diverse client needs. However, its private nature and lack of disclosed financials limit visibility. Key upcoming catalysts could include announcements of new strategic partnerships with major pharmaceutical companies, expansion of its service offerings into emerging modalities (e.g., cell therapies or gene therapy assays), or a significant funding round to scale operations and technology platform. These events would likely enhance the company's credibility and growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with a Top 20 Pharma Company30% success
• Q2 2027Expansion into Cell and Gene Therapy Assay Services40% success
• Q3 2026Series A Funding Round to Scale Operations50% success